Compliance Rate
Compliance Rate
59.0%
Compliant submissions
59
Incompliant submissions
41
Total trials
100
Your Clinical Trials
Showing 25 of 100 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/05/22
End: 01/07/22
Due: 01/08/22
Phase: N/A
Priority: Normal
Start: 01/15/22
End: 01/17/22
Due: 01/18/22
Phase: N/A
Priority: Normal
Start: 01/25/22
End: 01/27/22
Due: 01/28/22
Phase: N/A
Priority: Normal
Start: 02/04/22
End: 02/06/22
Due: 02/07/22
Phase: N/A
Priority: Normal
Start: 02/14/22
End: 02/16/22
Due: 02/17/22
Phase: N/A
Priority: Normal
Start: 02/24/22
End: 02/26/22
Due: 02/27/22
Phase: N/A
Priority: Normal
Start: 03/06/22
End: 03/08/22
Due: 03/09/22
Phase: N/A
Priority: Normal
Start: 03/16/22
End: 03/18/22
Due: 03/19/22
Phase: N/A
Priority: Normal
Start: 03/26/22
End: 03/28/22
Due: 03/29/22
Phase: N/A
Priority: Normal
Start: 04/05/22
End: 04/07/22
Due: 04/08/22
Phase: N/A
Priority: Normal
Start: 04/15/22
End: 04/17/22
Due: 04/18/22
Phase: N/A
Priority: Normal
Start: 07/04/22
End: 07/06/22
Due: 07/07/22
Phase: N/A
Priority: Normal
Start: 10/12/22
End: 10/14/22
Due: 10/15/22
Phase: N/A
Priority: Normal
Start: 03/31/23
End: 04/02/23
Due: 04/03/23
Phase: N/A
Priority: Normal
Start: 09/30/97
End: 09/30/13
Due: 09/30/14
Phase: N/A
Priority: Normal
Start: 09/30/96
End: 07/31/01
Due: 07/31/02
A Phase I Study of Combination Therapy With Didanosine (ddI) and Ribavirin in HIV-Infected Children.
Phase: N/A
Priority: Normal
Start: -
End: 07/31/98
Due: 07/31/99
Phase: N/A
Priority: Normal
Start: 01/31/99
End: 12/31/01
Due: 12/31/02
Phase: N/A
Priority: Normal
Start: 04/30/87
End: 12/31/98
Due: 12/31/99
Phase: N/A
Priority: Normal
Start: 12/31/84
End: -
Due: -
Phase: N/A
Priority: Normal
Start: -
End: 10/31/92
Due: 10/31/93
Phase: N/A
Priority: Normal
Start: -
End: 05/31/94
Due: 05/31/95
Phase: N/A
Priority: Normal
Start: 01/31/78
End: 02/28/79
Due: 02/28/80
Phase: N/A
Priority: Normal
Start: 10/31/97
End: 12/31/02
Due: 12/31/03
Phase: N/A
Priority: Normal
Start: -
End: 03/31/90
Due: 03/31/91
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Study 4 | NCT00000003 | Organization 4 | user4@example.com | Compliant | 2022-01-05 | 2022-01-07 | 2022-01-08 | 2025-07-01 | Researcher | 2025-07-01 |
| Study 14 | NCT00000013 | Organization 14 | user4@example.com | Compliant | 2022-01-15 | 2022-01-17 | 2022-01-18 | 2025-07-01 | Researcher | 2025-07-01 |
| Study 24 | NCT00000023 | Organization 24 | user4@example.com | Compliant | 2022-01-25 | 2022-01-27 | 2022-01-28 | 2025-07-01 | Researcher | 2025-07-01 |
| Study 34 | NCT00000033 | Organization 34 | user4@example.com | Incompliant | 2022-02-04 | 2022-02-06 | 2022-02-07 | 2025-07-01 | Researcher | 2025-07-01 |
| Study 44 | NCT00000043 | Organization 44 | user4@example.com | Compliant | 2022-02-14 | 2022-02-16 | 2022-02-17 | 2025-07-01 | Researcher | 2025-07-01 |
| Study 54 | NCT00000053 | Organization 54 | user4@example.com | Compliant | 2022-02-24 | 2022-02-26 | 2022-02-27 | 2025-07-01 | Researcher | 2025-07-01 |
| Study 64 | NCT00000063 | Organization 64 | user4@example.com | Compliant | 2022-03-06 | 2022-03-08 | 2022-03-09 | 2025-07-01 | Researcher | 2025-07-01 |
| Study 74 | NCT00000073 | Organization 74 | user4@example.com | Incompliant | 2022-03-16 | 2022-03-18 | 2022-03-19 | 2025-07-01 | Researcher | 2025-07-01 |
| Study 84 | NCT00000083 | Organization 84 | user4@example.com | Incompliant | 2022-03-26 | 2022-03-28 | 2022-03-29 | 2025-07-01 | Researcher | 2025-07-01 |
| Study 94 | NCT00000093 | Organization 94 | user4@example.com | Compliant | 2022-04-05 | 2022-04-07 | 2022-04-08 | 2025-07-01 | Researcher | 2025-07-01 |
| Study 104 | NCT00000103 | Organization 4 | user4@example.com | Compliant | 2022-04-15 | 2022-04-17 | 2022-04-18 | 2025-07-01 | Researcher | 2025-07-01 |
| Study 184 | NCT00000183 | Organization 84 | user4@example.com | Incompliant | 2022-07-04 | 2022-07-06 | 2022-07-07 | 2025-07-01 | Researcher | 2025-07-01 |
| Study 284 | NCT00000283 | Organization 84 | user4@example.com | Compliant | 2022-10-12 | 2022-10-14 | 2022-10-15 | 2025-07-01 | Researcher | 2025-07-01 |
| Study 454 | NCT00000453 | Organization 54 | user4@example.com | Compliant | 2023-03-31 | 2023-04-02 | 2023-04-03 | 2025-07-01 | Researcher | 2025-07-01 |
| Correction of Myopia Evaluation Trial (COMET) | NCT00000113 | Stony Brook University | user4@example.com | Compliant | 1997-09-30 | 2013-09-30 | 2014-09-30 | 2025-07-01 | - | 2025-07-14 |
| Doxycycline and OA Progression | NCT00000403 | Indiana University | user4@example.com | Compliant | 1996-09-30 | 2001-07-31 | 2002-07-31 | 2025-07-01 | - | 2025-07-14 |
| A Phase I Study of Combination Therapy With Didanosine (ddI) and Ribavirin in HIV-Infected Children. | NCT00000833 | National Institute of Allergy and Infectious Diseases (NIAID) | user4@example.com | Compliant | - | 1998-07-31 | 1999-07-31 | 2025-07-01 | - | 2025-07-14 |
| Effect of Nefazodone on Relapse in Females With Cocaine Abuse - 10 | NCT00000293 | National Institute on Drug Abuse (NIDA) | user4@example.com | Incompliant | 1999-01-31 | 2001-12-31 | 2002-12-31 | 2025-07-01 | - | 2025-07-14 |
| Post Coronary Artery Bypass Graft (CABG) Study | NCT00000463 | National Heart, Lung, and Blood Institute (NHLBI) | user4@example.com | Compliant | 1987-04-30 | 1998-12-31 | 1999-12-31 | 2025-07-01 | - | 2025-07-14 |
| Krypton-Argon Regression of Neovascularization Study (KARNS) | NCT00000153 | National Eye Institute (NEI) | user4@example.com | Compliant | 1984-12-31 | - | - | 2025-07-01 | - | 2025-07-14 |
| A Phase I Clinical Trial To Evaluate the Toxicity, Antiviral and Immunomodulatory Effects of a Range of Doses of Ampligen in HIV-Infected Subjects | NCT00000713 | National Institute of Allergy and Infectious Diseases (NIAID) | user4@example.com | Incompliant | - | 1992-10-31 | 1993-10-31 | 2025-07-01 | - | 2025-07-14 |
| Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients | NCT00000643 | National Institute of Allergy and Infectious Diseases (NIAID) | user4@example.com | Incompliant | - | 1994-05-31 | 1995-05-31 | 2025-07-01 | - | 2025-07-14 |
| The Berkeley Orthokeratology Study | NCT00000123 | National Eye Institute (NEI) | user4@example.com | Compliant | 1978-01-31 | 1979-02-28 | 1980-02-28 | 2025-07-01 | - | 2025-07-14 |
| Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children | NCT00000893 | National Institute of Allergy and Infectious Diseases (NIAID) | user4@example.com | Compliant | 1997-10-31 | 2002-12-31 | 2003-12-31 | 2025-07-01 | - | 2025-07-14 |
| Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members | NCT00000703 | National Institute of Allergy and Infectious Diseases (NIAID) | user4@example.com | Incompliant | - | 1990-03-31 | 1991-03-31 | 2025-07-01 | - | 2025-07-14 |